Frontlight ResearchEarly access
Not yet taking people in SwedenPhase 4
Tests lebrikizumab for eczema in adults and teens with moderate to severe atopic dermatitis
Tests lebrikizumab in people with moderate to severe atopic dermatitis, a type of eczema.
Key facts
- Who runs it
- Region Oestergoetland
- Where
- Falun, Goteborg, Linkoping, and Lund, SwedenSee the 4 sites
- Trial code
- Registry title
- An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 12 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults and adolescents with moderate to severe atopic dermatitis (eczema) who are candidates for systemic therapy and did not respond well enough to creams or ointments.
- Age
- Adults aged 18-64, and adolescents aged ≥12 to <18 years who weigh ≥40 kg (88 lb).
- Sex
- Men and women can join.
- Disease stage
- Moderate to severe atopic dermatitis (eczema). Candidates for systemic AD therapy.
- Earlier treatment
- A history of inadequate response to topical (skin) treatment, as assessed by the clinician.
Main reasons for not taking part
- Allergy to lebrikizumab or any of its ingredients
- Existing helminth (worm) infection
- Use of live or live attenuated vaccines at the same time
- Pregnant or breastfeeding women
- Cannot understand the study information in Swedish or English
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- The participant has given their written consent to participate in the trial
- Adults (aged 18-64) and adolescents (aged ≥12 to <18 years at the time of ICF/informed assent form (IAF) signature and weighing ≥40 kg) who are candidates for systemic AD therapy
- Diagnosis of AD and a history of inadequate topical treatment response as assessed by the clinician
- Adolescent participants (aged ≥12 to <18 years) must have their written informed consent signed by the parent/legal guardian. Adolescent participants from 15 years also need to give their own written consent to participate in the trial
Who cannot take part
- Concomitant use of live and live attenuated vaccines
- Hypersensitivity to the active substances or to any of the excipients of lebrikizumab
- Patients with pre-existing helminth infections
- Pregnant and/or breastfeeding women
- Patients unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study
- Patients unable to understand the study’s information and conduct in Swedish or English translations of the material
Where in Sweden
- Region DalarnaFalun, SwedenNot yet recruiting
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenNot yet recruiting
- Region OestergoetlandLinkoping, SwedenNot yet recruiting
- Region Skane Skanes UniversitetssjukhusLund, SwedenNot yet recruiting
About the trial
What the trial wants to find out
The primary objective of this trial is to confirm the effectiveness of lebrikizumab in improving eczema in patients with moderate-to-severe AD.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and non-lesional skin in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
- Plain-language title
- Tests lebrikizumab for eczema in adults and teens with moderate to severe atopic dermatitisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 12 February 2026